Provident Co of the Employees of the Hebrew University LTD lessened its stake in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 20.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,113 shares of the company’s stock after selling 4,097 shares during the quarter. Moderna accounts for approximately 0.8% of Provident Co of the Employees of the Hebrew University LTD’s holdings, making the stock its 27th biggest position. Provident Co of the Employees of the Hebrew University LTD’s holdings in Moderna were worth $669,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of MRNA. Knuff & Co LLC boosted its stake in Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after purchasing an additional 244 shares during the last quarter. Allworth Financial LP boosted its position in shares of Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after buying an additional 281 shares during the last quarter. Howard Capital Management Inc. raised its position in Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after buying an additional 297 shares during the last quarter. Larson Financial Group LLC raised its position in Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after buying an additional 317 shares during the last quarter. Finally, Empowered Funds LLC boosted its holdings in shares of Moderna by 6.6% during the 3rd quarter. Empowered Funds LLC now owns 5,199 shares of the company’s stock valued at $347,000 after acquiring an additional 322 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.
Moderna Trading Up 0.9 %
NASDAQ:MRNA opened at $34.62 on Monday. The business’s 50-day moving average is $35.94 and its 200 day moving average is $47.15. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47. The company has a market capitalization of $13.36 billion, a P/E ratio of -3.73 and a beta of 1.86.
Analyst Ratings Changes
View Our Latest Stock Analysis on MRNA
Moderna Company Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
- Five stocks we like better than Moderna
- What Is WallStreetBets and What Stocks Are They Targeting?
- How to Build the Ultimate Everything ETF Portfolio
- What is an Earnings Surprise?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.